EMD Millipore to Showcase Drug Bioavailability Solutions and Expanded Chemical and Reagent Portfolio at AAPS

01 Oct 2012
Share
EMD Millipore will be presenting the latest innovations for enhancing drug bioavailability, decreasing solvents waste and exposure, and expansion/harmonization of chemicals and reagents at American Association of Pharmaceutical Scientists (AAPS) from October 14th to 18th 2012 in Chicago, Illinois.

Bioavailability
EMD Millipore offers a broad portfolio of products and technologies for enhancing drug bioavailability. Supported by a legacy of expertise with pharmaceutical raw materials, the portfolio includes solutions to address all major aspects of bioavailability including solubility, PK/PD modifiers, targeting, and optimized formulation. Bioavailability solutions from EMD Millipore offer a unique blend of broad experience, deep application know-how, and cGMP production capabilities to support customers from API development to registration of the final dosage form.


Expanded Chemical and Reagents Portfolio
Previously only available outside North America, this portfolio of more than 14,000 products will enable customers in R&D and analytical labs in North America to access the same products of exacting quality, using the same product codes, as colleagues in other countries. Global standardization of EMD Millipore's product offerings translates into a harmonized solution, in addition to providing North American customers a greater choice including a wider range of pack sizes. The products offer superior specifications and innovative, environmentally friendly packaging for less waste and greater safety.

EMD Millipore's EMD ReCyclerTM program
This innovative solution significantly reduces the waste typically associated with solvent usage and disposal, decreasing the carbon footprint. In addition, the service reduces researchers' exposure to solvents associated with use of small, disposable containers increasing the safety of the lab and those who work in it.

EMD Millipore technical experts will be presenting the following posters:

Enantiomerically Pure Cationic Lipids: Tailored Formulations for Specific Applications
Monday, October 15, 1:30-4:30pm, Hall F

ODT formulations with aqueous coatings?
Tuesday, October 16, 9:30-12:30pm, Hall F

Roll compaction of mannitol: Tableting behavior of various spray-dried mannitols before and after dry granulation
Wednesday, October 17, 9:30-12:30pm, Hall F

In Vitro, in Silico and in Vivo Evaluation of a Novel Porous Silica to Enhance the Bioavailability of Fenofibrate
Wednesday, October 17, 1:30-4:30pm, Hall F

In Vitro Evaluation of Novel Silica Materials to Enhance the Dissolution Rate of Fenofibrate and Itraconazole
Thursday, October 18, 8:30-11:30am, Hall F

As well as the following technical session:

Challenges and Strategies for Biosimilars Manufacturing
Monday, October 15, 1:30-4:00pm

Visit Booth #1819 to find out more!

Request Info


Company website

EMD Millipore, a division of Merck KGaA, Darmstadt, Germany